Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Controlled Trail to Evaluate Efficacy and Safety of Sequential Neo-adjuvant Chemotherapy Plus Surgery Followed by Capecitabine Versus Conventional Postoperative Adjuvant Chemotherapy

NCT03011060 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT03011060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03011060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Controlled Trail to Evaluate Efficacy and Safety of Sequential Neo-adjuvant Chemotherapy Plus Surgery Followed by Capecitabine Versus Conventional Postoperative Adjuvant Chemotherapy
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2016
Completion date
February 28, 2025
Enrollment
1,588 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female